The benefits of weight loss surgery for younger patients may persist for years.

Weight loss surgery helping in the reduction of type 2 diabetes, hypertension, dyslipidemia, cardiovascular disease sexual dysfunction -- even mortality rate.

Baritastic is a tool for your patients. Already the most robust app built specifically for the bariatric patient, now your program can connect, support, and monitor your patients using the Baritastic app. They use many of the same features in Baritastic to create a unique free app specifically for your program.

Are you changing your criteria for recommending metabolic surgery to your patients based on the new guidelines issued by International Diabetes Federation Taskforce on Epidemiology and Prevention of Diabetes (see article 1)?

In this exclusive interview, Dr. Vinik shares his views on what matters in studying bariatric surgery outcomes, and why weight loss and effect on diabetes are not the key questions for him.

42 year old female, 5’ 4”, 275 lbs, BMI 47.2 kg/m2. History of hypertension, chronic low back pain, severe gastroesophageal reflux disease, depression and type 2 diabetes (diagnosed 2 years ago), and anxiety/depression. Medications include lisinopril 10 mg daily, oxycodone 5 mg TID prn, omeprazole 20 mg daily, metformin 500 mg BID, and paroxetine 20 mg daily. She has been actively working with her PCP on losing weight with diet modification and water aerobics but has only lost about 4% of her weight in the past 6 months. Current labs: (fasting) blood glucose 154 mg/dl, Hgb A1c 6.7 Creatinine 1.6, mg/dl and TSH of 3.6 U/ml. What is the best course of action?

Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 6 of this Exclusive Interview, Steve asks Dr. Vinik his opinion on type 1 and SGLT-2s.

Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 5 of this Exclusive Interview, Dr. Vinik explains the caution on the part of doctors to use the latest SGLT-2 medications despite apparent benefits.

Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida. In Part 3 of this Exclusive Interview, he explains the most important risk factors to look for when determining how to treat a patient. Aaron Vinik, MD, PhD, FCP, MACP, FACE is …

Dr. Aaron Vinik joins Diabetes in Control publisher Steve Freed at the AACE 2016 convention in Orlando, Florida In Part 2 of this Exclusive Interview, Dr. Vinik discusses using heart rate variability as a risk identifier in the treatment of patients with high blood glucose. Aaron Vinik, MD, PhD, FCP, MACP, …